Eli Lilly | LLY - Equity Capital And Reserves



Eli Lilly reported $18.27B in Equity Capital and Reserves for its fiscal quarter ending in June of 2025.


Equity Capital And Reserves Change Date
AbbVie USD 1.46B 1.86B Mar/2025
Abbott USD 50.83B 1.76B Jun/2025
ALKERMES USD 1.62B 113M Jun/2025
Amgen USD 7.43B 1.22B Jun/2025
AstraZeneca USD 44.72B 3.68B Jun/2025
Baxter International USD 7.05B 90M Mar/2025
Biogen USD 17.63B 655.3M Jun/2025
Bristol-Myers Squibb USD 17.49B 100M Jun/2025
Drreddys Laboratories INR 353.76B 36.03B Jun/2025
Eli Lilly USD 18.27B 2.43B Jun/2025
Gilead Sciences USD 19.67B 596M Jun/2025
GlaxoSmithKline GBP 14.35B 197M Jun/2025
Glaxosmithkline GBP 14.35B 683M Jun/2025
J&J USD 78.11B 6.62B Mar/2025
Medtronic USD 48.02B 1.36B Apr/2025
Merck USD 49.06B 725M Jun/2025
Neurocrine Biosciences USD 2.69B 158.6M Jun/2025
Novartis USD 42.05B 3.6B Jun/2025
Novartis USD 42.05B 1.99B Jun/2025
Novo Nordisk 168.07B 29.53B Jun/2025
Perrigo USD 4.47B 108.3M Jun/2025
Pfizer USD 88.7B 1.64B Jun/2025
Prestige Brands USD 1.86B 20.58M Jun/2025
Regeneron Pharmaceuticals USD 29.94B 551.3M Jun/2025
Roche Holding CHF 36.16B 3.28B Dec/2024
Sanofi 70.28B 3.8B Jun/2025
Sanofi 70.28B 7.58B Jun/2025
United Therapeutics USD 7.17B 366.4M Jun/2025
Zoetis USD 4.98B 322M Jun/2025